Evidence map›Paper›PMID 39282115›Full record

ArticlePeerJ2024

Radical chemoradiotherapy for superficial esophageal cancer complicated with liver cirrhosis.

Hejing Bao, Hehong Bao, Liping Lin, Yuhuan Wang, Longbin Zhang, Li Zhang, Han Zhang, Lingxiang Liu, Xiaolong Cao

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hejing BaoDepartment of Oncology, The Affiliated Panyu Center Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Hehong BaoDepartment of Psychosomatic Medicine, Chongqing University Three Gorges Hospital, Wanzhou, Chongqing, China.
Liping LinDepartment of Oncology, The Affiliated Panyu Center Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Yuhuan WangDepartment of Oncology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China.
Longbin ZhangDepartment of Oncology, Chongqing University Three Gorges Hospital, Wanzhou, Chongqing, China.
Li ZhangDepartment of Oncology, Chongqing University Three Gorges Hospital, Wanzhou, Chongqing, China.
Han ZhangDepartment of Oncology, Chongqing University Three Gorges Hospital, Wanzhou, Chongqing, China.
Lingxiang LiuDepartment of Oncology, The Affiliated Panyu Center Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Xiaolong CaoDepartment of Oncology, The Affiliated Panyu Center Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although chemoradiotherapy is an effective treatment for esophageal cancer, its feasibility in esophageal cancer with cirrhosis remains largely unclear. Methods: We retrospectively studied 11 patients with superficial esophageal cancer with liver cirrhosis (Child-Pugh score ≤8) who underwent radical chemoradiotherapy from four centers, and the overall survival rate, local control rate and adverse events at 1 and 3 years were explored. Results: The median age of the included patients was 67 years (Inter-Quartile Range 60-75 years). Complete response was observed in most patients ( Conclusion: Radical chemoradiotherapy is a potential treatment option for patients with superficial esophageal cancer complicated with cirrhosis. However, it can increase the risk of bleeding, which warrants prompt recognition and intervention.

Indexed as

ChemoradiotherapyEsophageal NeoplasmsLiver CirrhosisAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeLiver cirrhosisRadical chemoradiotherapyRetrospective studySuperficial esophageal cancer

Identifiers

PMID39282115
PMCPMC11401512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.